Northern Trust
LXEO icon

Northern Trust’s Lexeo Therapeutics LXEO Stock Holding History

Northern Trust’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.04M Buy
867,391
+373,725
+76% +$2.02M ﹤0.01% 2740
2026
Q1 		$2.83M Buy
493,666
+36,614
+8% +$259K ﹤0.01% 2782
2025
Q4 		$4.54M Buy
457,052
+220,599
+93% +$2.01M ﹤0.01% 2530
2025
Q3 		$1.57M Buy
236,453
+35,667
+18% +$172K ﹤0.01% 3165
2025
Q2 		$807K Sell
200,786
-5,307
-3% -$17.5K ﹤0.01% 3494
2025
Q1 		$715K Sell
206,093
-8,191
-4% -$36.3K ﹤0.01% 3417
2024
Q4 		$1.41M Buy
214,284
+14,185
+7% +$112K ﹤0.01% 3212
2024
Q3 		$1.81M Buy
200,099
+105,192
+111% +$1.25M ﹤0.01% 3063
2024
Q2 		$1.52M Buy
94,907
+12,806
+16% +$186K ﹤0.01% 3055
2024
Q1 		$1.29M Buy
82,101
+66,512
+427% +$1.04M ﹤0.01% 3198
2023
Q4 		$209K Buy
+15,589
New +$194K ﹤0.01% 3883

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Northern Trust's LXEO Position: Q2 2026 in Review

Northern Trust increased its Lexeo Therapeutics (LXEO) stake by 76% in Q2 2026, buying an estimated $2.02M and bringing the position to 867,391 shares worth $4.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

Northern Trust first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.54M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Northern Trust held 867,391 shares of Lexeo Therapeutics worth $4.04M as of Q2 2026.
  • Northern Trust bought 373,725 Lexeo Therapeutics shares in Q2 2026, an estimated $2.02M.
  • Lexeo Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2740 holding.
  • Northern Trust first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Northern Trust's Lexeo Therapeutics position peaked at $4.54M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.